Vertex Pharmaceuticals (VRTX) Other financing activities (2009 - 2026)

Vertex Pharmaceuticals' Other financing activities history runs 18 years deep, the most recent figure standing at -$400000.0 for Q1 2026.

• On a quarterly basis, Other financing activities fell 102.4% year-over-year to -$400000.0 in Q1 2026; TTM through Mar 2026 was -$13.4 million, a 111.71% decrease from a year earlier, with the FY2025 full-year figure at $3.7 million, down 96.77% from the prior year.
• Other financing activities retreated to -$400000.0 in Q1 2026 per VRTX's latest filing, from $1.1 million in the prior quarter.
• Across five years, Other financing activities topped out at $109.3 million in Q4 2024 and bottomed at -$131.2 million in Q4 2022.
• The 5-year median for Other financing activities is $1.1 million (2023), against an average of $7.2 million.
• Across the five-year window, Other financing activities plunged 289.89% in 2023 and jumped 7386.67% in 2024, its largest moves.
• Year by year, Other financing activities stood at -$131.2 million in 2022, then soared by 98.86% to -$1.5 million in 2023, then soared by 7386.67% to $109.3 million in 2024, then tumbled by 98.99% to $1.1 million in 2025, then plunged by 136.36% to -$400000.0 in 2026.
• Per Business Quant, the three latest VRTX Other financing activities figures stand at -$400000.0 (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025).